サンプル依頼リスト カート
  • English
デフォルト表紙
市場調査レポート
商品コード
1730936

ループス腎炎の世界市場レポート 2025年

Lupus Nephritis Global Market Report 2025

出版日
ページ情報
英文 175 Pages
納期
2～10営業日
カスタマイズ可能
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=144.87円
ループス腎炎の世界市場レポート 2025年
出版日: 2025年05月16日
発行: The Business Research Company
ページ情報: 英文 175 Pages
納期: 2～10営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

ループス腎炎市場規模は、今後数年間で力強い成長が見込まれます。2029年にはCAGR7.6％で28億米ドルに成長します。予測期間中の成長は、医師の意識の高まり、生物学的療法の採用拡大、専門クリニックの増加、腎移植への重点化、腎臓内科サービスへのアクセス改善などの要因によるものと考えられます。予測期間における主な動向としては、生物学的療法の進歩、個別化医療へのアプローチ、新規診断バイオマーカーの発見、臨床試験の拡大、幹細胞治療の進歩などが挙げられます。

遺伝的素因の有病率の増加は、今後のループス腎炎市場の成長を牽引すると予想されます。遺伝的素因とは、特定の疾患や病態を発症しやすくする遺伝的形質のことです。遺伝、環境の影響、遺伝子の突然変異などの要因が、遺伝的素因の有病率の上昇に寄与しています。この素因はループス腎炎の開発において主な役割を果たしており、特に腎機能に影響を及ぼす自己免疫疾患における遺伝的要因の影響にハイライトを当てています。例えば、2024年10月、嚢胞性線維症トラストは、英国CFレジストリが2022年に1万1,148人の患者を記録し、2024年には1万1,318人に増加したと報告しました。したがって、遺伝的素因の有病率の増加がループス腎炎市場の成長に寄与しています。

ループス腎炎市場の各社は、患者の治療成績と長期的な腎機能を改善するため、先進的な第2世代カルシニューリン阻害剤の開発に注力しています。これらの阻害剤は、ループス腎炎において、免疫反応を調節することにより炎症を抑え、腎臓障害を予防するために使用されます。例えば、2024年9月、アウリニア製薬株式会社は、ループス腎炎の治療薬としてLUPKYNIS（一般名ボクロスポリン）の承認を厚生労働省から取得しました。今回の承認は、本剤の安全性と有効性を実証したアウローラ臨床プログラムの良好な結果に基づき、ミコフェノール酸モフェチル（MMF）との併用が認められたものです。今回の承認は、日本におけるループス腎炎患者の治療選択肢を拡大し、疾患管理と予後を改善する上で大きな前進となります。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場- マクロ経済シナリオ金利、インフレ、地政学、新型コロナウイルス感染症の影響と回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

  • 世界のループス腎炎PESTEL分析（政治、社会、技術、環境、法的要因、促進要因と抑制要因）
  • 最終用途産業の分析
  • 世界のループス腎炎市場：成長率分析
  • 世界のループス腎炎市場の実績：規模と成長、2019年～2024年
  • 世界のループス腎炎市場の予測：規模と成長、2024年～2029年、2034年
  • 世界のループス腎炎総アドレス可能市場（TAM）

第6章 市場セグメンテーション

  • 世界のループス腎炎市場：ステージ別、実績と予測、2019年～2024年、2024年～2029年、2034年
  • クラス1
  • クラス2
  • クラス3
  • その他のステージ
  • 世界のループス腎炎市場：薬剤クラス別、実績と予測、2019年～2024年、2024年～2029年、2034年
  • 免疫抑制薬
  • コルチコステロイド
  • 生物学的因子
  • 抗マラリア薬
  • 世界のループス腎炎市場：投与経路別、実績と予測、2019年～2024年、2024年～2029年、2034年
  • オーラル
  • 非経口
  • その他の投与経路
  • 世界のループス腎炎市場：流通チャネル別、実績と予測、2019年～2024年、2024年～2029年、2034年
  • 病院薬局
  • 小売薬局
  • オンライン薬局
  • 世界のループス腎炎市場：エンドユーザー別、実績と予測、2019年～2024年、2024年～2029年、2034年
  • 病院
  • 専門クリニック
  • その他のエンドユーザー
  • 世界のループス腎炎市場、クラス1のサブセグメンテーション、タイプ別、実績と予測、2019年～2024年、2024年～2029年、2034年
  • 無症状の症例
  • 軽度のタンパク尿
  • 偶発的な診断
  • 世界のループス腎炎市場、クラス2のサブセグメンテーション、タイプ別、実績と予測、2019年～2024年、2024年～2029年、2034年
  • 軽度の血尿
  • 低度タンパク尿
  • 最小限の免疫複合体沈着
  • 世界のループス腎炎市場、クラス3のサブセグメンテーション、タイプ別、実績と予測、2019年～2024年、2024年～2029年、2034年
  • 活動性病変
  • 慢性硬化性病変
  • 三日月形
  • 世界のループス腎炎市場、その他のステージのサブセグメンテーション、タイプ別、実績と予測、2019年～2024年、2024年～2029年、2034年
  • クラス4（びまん性ループス腎炎）
  • クラス5（膜性ループス腎炎）
  • クラス6（進行性硬化性ループス腎炎）

第7章 地域別・国別分析

  • 世界のループス腎炎市場：地域別、実績と予測、2019年～2024年、2024年～2029年、2034年
  • 世界のループス腎炎市場：国別、実績と予測、2019年～2024年、2024年～2029年、2034年

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

  • ループス腎炎市場：競合情勢
  • ループス腎炎市場：企業プロファイル
    • F. Hoffmann-La Roche Ltd. Overview, Products and Services, Strategy and Financial Analysis
    • Bristol Myers Squibb Overview, Products and Services, Strategy and Financial Analysis
    • Novartis AG Overview, Products and Services, Strategy and Financial Analysis
    • GlaxoSmithKline plc Overview, Products and Services, Strategy and Financial Analysis
    • Eli Lilly and Company Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

  • Genentech
  • Astrazeneca PLC
  • Biocon Biologics
  • Hanmi Pharmaceutical Co. Ltd.
  • Sana Biotechnology Inc.
  • RemeGen Co. Ltd.
  • Aurinia Pharmaceuticals Inc.
  • Otsuka Pharmaceutical Co. Ltd.
  • Equillium Inc.
  • Anthera Pharmaceuticals Inc.
  • Atara Biotherapeutics Inc.
  • Artiva Biotherapeutics
  • Caribou Biosciences
  • Nkarta Inc.
  • Adicet Bio Inc.

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

  • ループス腎炎市場2029年：新たな機会を提供する国
  • ループス腎炎市場2029年：新たな機会を提供するセグメント
  • ループス腎炎市場2029年：成長戦略
    • 市場動向に基づく戦略
    • 競合の戦略

第36章 付録

目次
Product Code: r34608

Lupus nephritis is a severe kidney condition caused by systemic lupus erythematosus (SLE), an autoimmune disease in which the immune system erroneously attacks healthy tissues, including the kidneys. This inflammation can result in kidney damage, reduced function, and, if left untreated, potentially lead to kidney failure. Early diagnosis and treatment are essential for managing the disease effectively.

Lupus nephritis progresses through different stages, including class 1, class 2, class 3, and others. Class 1 represents a stage with minimal kidney damage, where kidney function remains stable, and symptoms are generally not apparent. Treatment at this stage focuses on preventing further progression of the disease. Common drug classes used in treatment include immunosuppressive drugs, corticosteroids, biological agents, and antimalarial drugs, which can be administered orally, parenterally, and through other routes. These treatments are distributed through hospital pharmacies, retail pharmacies, and online pharmacies, with end users such as hospitals, specialty clinics, and others.

The lupus nephritis market research report is one of a series of new reports from The Business Research Company that provides lupus nephritis market statistics, including lupus nephritis industry global market size, regional shares, competitors with a lupus nephritis market share, detailed lupus nephritis market segments, market trends and opportunities, and any further data you may need to thrive in the lupus nephritis industry. This lupus nephritis market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The lupus nephritis market size has grown strongly in recent years. It will grow from $1.94 billion in 2024 to $2.09 billion in 2025 at a compound annual growth rate (CAGR) of 7.9%. The growth during the historic period can be attributed to factors such as increased research investments in lupus nephritis, a rising incidence of autoimmune diseases, higher healthcare spending, the growing adoption of biologics, and the increasing popularity of telemedicine.

The lupus nephritis market size is expected to see strong growth in the next few years. It will grow to $2.80 billion in 2029 at a compound annual growth rate (CAGR) of 7.6%. The growth during the forecast period can be attributed to factors such as the rising awareness among physicians, greater adoption of biologic therapies, an increasing number of specialty clinics, a growing emphasis on renal transplantation, and improved access to nephrology services. Key trends in the forecast period include advancements in biologic therapies, personalized medicine approaches, the discovery of novel diagnostic biomarkers, an expansion of clinical trials, and progress in stem cell therapy.

The increasing prevalence of genetic predisposition is expected to drive the growth of the lupus nephritis market in the future. Genetic predisposition refers to inherited genetic traits that make an individual more likely to develop certain diseases or conditions. Factors such as inheritance, environmental influences, and gene mutations contribute to the rising prevalence of genetic predisposition. This predisposition plays a key role in the development of lupus nephritis, highlighting the influence of inherited genetic factors in autoimmune diseases, particularly those affecting kidney function. For example, in October 2024, the Cystic Fibrosis Trust reported that the UK CF Registry recorded 11,148 patients in 2022, which increased to 11,318 in 2024, reflecting a 1.52% rise in cystic fibrosis (CF) patients. Therefore, the growing prevalence of genetic predisposition is contributing to the growth of the lupus nephritis market.

Companies in the lupus nephritis market are focusing on developing advanced second-generation calcineurin inhibitors to improve treatment outcomes and long-term kidney function for patients. These inhibitors are used in lupus nephritis to reduce inflammation and prevent kidney damage by modulating immune responses. For example, in September 2024, Aurinia Pharmaceuticals Inc. received approval from the Japanese Ministry of Health, Labour, and Welfare for LUPKYNIS (voclosporin) as a treatment for lupus nephritis. This approval allows voclosporin to be used in combination with mycophenolate mofetil (MMF), based on the positive results from the AURORA Clinical Program, which demonstrated the drug's safety and efficacy. This approval marks a significant step forward in expanding treatment options for lupus nephritis patients in Japan, improving both disease management and outcomes.

In March 2024, Lupus Therapeutics, an affiliate clinical research partner of the Lupus Research Alliance, partnered with Artiva Biotherapeutics Inc. to support a clinical trial for lupus nephritis. This collaboration aims to conduct a Phase 1 trial to evaluate Artiva's AlloNK therapy with anti-CD20 antibodies for patients with active lupus nephritis. The trial will assess the safety and effectiveness of this potential treatment for this severe kidney complication. Artiva Biotherapeutics is a biotechnology company based in the US that develops treatments for lupus nephritis.

Major players in the lupus nephritis market are F. Hoffmann-La Roche Ltd., Bristol Myers Squibb, Novartis AG, GlaxoSmithKline plc, Eli Lilly and Company, Genentech, Astrazeneca PLC, Biocon Biologics, Hanmi Pharmaceutical Co. Ltd., Sana Biotechnology Inc., RemeGen Co. Ltd., Aurinia Pharmaceuticals Inc., Otsuka Pharmaceutical Co. Ltd., Equillium Inc., Anthera Pharmaceuticals Inc., Atara Biotherapeutics Inc., Artiva Biotherapeutics, Caribou Biosciences, Nkarta Inc., Adicet Bio Inc., Lupus Research Alliance, Kyverna Therapeutics Inc., Kezar Life Sciences, and Bionxt Solutions.

Asia-Pacific was the largest region in the lupus nephritis market in 2024. The regions covered in lupus nephritis report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the lupus nephritis market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The lupus nephritis market consists of revenues earned by entities by providing services such as dialysis services, diagnostic testing, renal care services, and home healthcare services. The market value includes the value of related goods sold by the service provider or included within the service offering. The lupus nephritis market also consists of sales of medical devices, diagnostic products, and renal replacement products. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Lupus Nephritis Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on lupus nephritis market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

  • Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
  • Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market shares.
  • Benchmark performance against key competitors.
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis
  • Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
  • All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for lupus nephritis ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The lupus nephritis market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

  • The market characteristics section of the report defines and explains the market.
  • The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
  • The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

  • Market segmentations break down the market into sub markets.
  • The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
  • The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
  • The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

  • Markets Covered:1) By Stage: Class 1; Class 2; Class 3; Other Stages
  • 2) By Drug Class: Immunosuppressive Drugs; Corticosteroids; Biological Agents; Antimalarial Drugs
  • 3) Route Of Administration: Oral; Parenteral; Other Routes Of Administration
  • 4) By Distribution Channel: Hospital Pharmacy; Retail Pharmacy; Online Pharmacy
  • 5) By End-User: Hospitals; Specialty Clinics; Other End-Users
  • Subsegments:
  • 1) By Class 1: Asymptomatic Cases; Mild Proteinuria; Incidental Diagnosis.
  • 2) By Class 2: Mild Hematuria; Low-Grade Proteinuria; Minimal Immune Complex Deposition.
  • 3) By Class 3: Active Lesions; Chronic Sclerotic Lesions; Crescent Formation.
  • 4) By Other Stages: Class 4 (Diffuse Lupus Nephritis); Class 5 (Membranous Lupus Nephritis); Class 6 (Advanced Sclerotic Lupus Nephritis)
  • Companies Mentioned: F. Hoffmann-La Roche Ltd.; Bristol Myers Squibb; Novartis AG; GlaxoSmithKline plc; Eli Lilly and Company
  • Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
  • Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
  • Time series: Five years historic and ten years forecast.
  • Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
  • Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
  • Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
  • Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Lupus Nephritis Market Characteristics

3. Lupus Nephritis Market Trends And Strategies

4. Lupus Nephritis Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market

5. Global Lupus Nephritis Growth Analysis And Strategic Analysis Framework

  • 5.1. Global Lupus Nephritis PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
  • 5.2. Analysis Of End Use Industries
  • 5.3. Global Lupus Nephritis Market Growth Rate Analysis
  • 5.4. Global Lupus Nephritis Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
  • 5.5. Global Lupus Nephritis Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
  • 5.6. Global Lupus Nephritis Total Addressable Market (TAM)

6. Lupus Nephritis Market Segmentation

  • 6.1. Global Lupus Nephritis Market, Segmentation By Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Class 1
  • Class 2
  • Class 3
  • Other Stages
  • 6.2. Global Lupus Nephritis Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Immunosuppressive Drugs
  • Corticosteroids
  • Biological Agents
  • Antimalarial Drugs
  • 6.3. Global Lupus Nephritis Market, Segmentation Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Oral
  • Parenteral
  • Other Routes Of Administration
  • 6.4. Global Lupus Nephritis Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy
  • 6.5. Global Lupus Nephritis Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Hospitals
  • Speciality Clinics
  • Other End-Users
  • 6.6. Global Lupus Nephritis Market, Sub-Segmentation Of Class 1, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Asymptomatic Cases
  • Mild Proteinuria
  • Incidental Diagnosis
  • 6.7. Global Lupus Nephritis Market, Sub-Segmentation Of Class 2, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Mild Hematuria
  • Low-Grade Proteinuria
  • Minimal Immune Complex Deposition
  • 6.8. Global Lupus Nephritis Market, Sub-Segmentation Of Class 3, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Active Lesions
  • Chronic Sclerotic Lesions
  • Crescent Formation
  • 6.9. Global Lupus Nephritis Market, Sub-Segmentation Of Other Stages, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Class 4 (Diffuse Lupus Nephritis)
  • Class 5 (Membranous Lupus Nephritis)
  • Class 6 (Advanced Sclerotic Lupus Nephritis)

7. Lupus Nephritis Market Regional And Country Analysis

  • 7.1. Global Lupus Nephritis Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 7.2. Global Lupus Nephritis Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Lupus Nephritis Market

  • 8.1. Asia-Pacific Lupus Nephritis Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 8.2. Asia-Pacific Lupus Nephritis Market, Segmentation By Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 8.3. Asia-Pacific Lupus Nephritis Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 8.4. Asia-Pacific Lupus Nephritis Market, Segmentation Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Lupus Nephritis Market

  • 9.1. China Lupus Nephritis Market Overview
  • 9.2. China Lupus Nephritis Market, Segmentation By Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
  • 9.3. China Lupus Nephritis Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
  • 9.4. China Lupus Nephritis Market, Segmentation Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Lupus Nephritis Market

  • 10.1. India Lupus Nephritis Market, Segmentation By Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 10.2. India Lupus Nephritis Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 10.3. India Lupus Nephritis Market, Segmentation Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Lupus Nephritis Market

  • 11.1. Japan Lupus Nephritis Market Overview
  • 11.2. Japan Lupus Nephritis Market, Segmentation By Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 11.3. Japan Lupus Nephritis Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 11.4. Japan Lupus Nephritis Market, Segmentation Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Lupus Nephritis Market

  • 12.1. Australia Lupus Nephritis Market, Segmentation By Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 12.2. Australia Lupus Nephritis Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 12.3. Australia Lupus Nephritis Market, Segmentation Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Lupus Nephritis Market

  • 13.1. Indonesia Lupus Nephritis Market, Segmentation By Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 13.2. Indonesia Lupus Nephritis Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 13.3. Indonesia Lupus Nephritis Market, Segmentation Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Lupus Nephritis Market

  • 14.1. South Korea Lupus Nephritis Market Overview
  • 14.2. South Korea Lupus Nephritis Market, Segmentation By Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 14.3. South Korea Lupus Nephritis Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 14.4. South Korea Lupus Nephritis Market, Segmentation Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Lupus Nephritis Market

  • 15.1. Western Europe Lupus Nephritis Market Overview
  • 15.2. Western Europe Lupus Nephritis Market, Segmentation By Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 15.3. Western Europe Lupus Nephritis Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 15.4. Western Europe Lupus Nephritis Market, Segmentation Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Lupus Nephritis Market

  • 16.1. UK Lupus Nephritis Market, Segmentation By Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 16.2. UK Lupus Nephritis Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 16.3. UK Lupus Nephritis Market, Segmentation Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Lupus Nephritis Market

  • 17.1. Germany Lupus Nephritis Market, Segmentation By Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 17.2. Germany Lupus Nephritis Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 17.3. Germany Lupus Nephritis Market, Segmentation Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Lupus Nephritis Market

  • 18.1. France Lupus Nephritis Market, Segmentation By Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 18.2. France Lupus Nephritis Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 18.3. France Lupus Nephritis Market, Segmentation Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Lupus Nephritis Market

  • 19.1. Italy Lupus Nephritis Market, Segmentation By Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 19.2. Italy Lupus Nephritis Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 19.3. Italy Lupus Nephritis Market, Segmentation Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Lupus Nephritis Market

  • 20.1. Spain Lupus Nephritis Market, Segmentation By Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 20.2. Spain Lupus Nephritis Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 20.3. Spain Lupus Nephritis Market, Segmentation Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Lupus Nephritis Market

  • 21.1. Eastern Europe Lupus Nephritis Market Overview
  • 21.2. Eastern Europe Lupus Nephritis Market, Segmentation By Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 21.3. Eastern Europe Lupus Nephritis Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 21.4. Eastern Europe Lupus Nephritis Market, Segmentation Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Lupus Nephritis Market

  • 22.1. Russia Lupus Nephritis Market, Segmentation By Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 22.2. Russia Lupus Nephritis Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 22.3. Russia Lupus Nephritis Market, Segmentation Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Lupus Nephritis Market

  • 23.1. North America Lupus Nephritis Market Overview
  • 23.2. North America Lupus Nephritis Market, Segmentation By Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 23.3. North America Lupus Nephritis Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 23.4. North America Lupus Nephritis Market, Segmentation Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Lupus Nephritis Market

  • 24.1. USA Lupus Nephritis Market Overview
  • 24.2. USA Lupus Nephritis Market, Segmentation By Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 24.3. USA Lupus Nephritis Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 24.4. USA Lupus Nephritis Market, Segmentation Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Lupus Nephritis Market

  • 25.1. Canada Lupus Nephritis Market Overview
  • 25.2. Canada Lupus Nephritis Market, Segmentation By Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 25.3. Canada Lupus Nephritis Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 25.4. Canada Lupus Nephritis Market, Segmentation Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Lupus Nephritis Market

  • 26.1. South America Lupus Nephritis Market Overview
  • 26.2. South America Lupus Nephritis Market, Segmentation By Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 26.3. South America Lupus Nephritis Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 26.4. South America Lupus Nephritis Market, Segmentation Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Lupus Nephritis Market

  • 27.1. Brazil Lupus Nephritis Market, Segmentation By Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 27.2. Brazil Lupus Nephritis Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 27.3. Brazil Lupus Nephritis Market, Segmentation Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Lupus Nephritis Market

  • 28.1. Middle East Lupus Nephritis Market Overview
  • 28.2. Middle East Lupus Nephritis Market, Segmentation By Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 28.3. Middle East Lupus Nephritis Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 28.4. Middle East Lupus Nephritis Market, Segmentation Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Lupus Nephritis Market

  • 29.1. Africa Lupus Nephritis Market Overview
  • 29.2. Africa Lupus Nephritis Market, Segmentation By Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 29.3. Africa Lupus Nephritis Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 29.4. Africa Lupus Nephritis Market, Segmentation Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Lupus Nephritis Market Competitive Landscape And Company Profiles

  • 30.1. Lupus Nephritis Market Competitive Landscape
  • 30.2. Lupus Nephritis Market Company Profiles
    • 30.2.1. F. Hoffmann-La Roche Ltd. Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.2. Bristol Myers Squibb Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.3. Novartis AG Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.4. GlaxoSmithKline plc Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.5. Eli Lilly and Company Overview, Products and Services, Strategy and Financial Analysis

31. Lupus Nephritis Market Other Major And Innovative Companies

  • 31.1. Genentech
  • 31.2. Astrazeneca PLC
  • 31.3. Biocon Biologics
  • 31.4. Hanmi Pharmaceutical Co. Ltd.
  • 31.5. Sana Biotechnology Inc.
  • 31.6. RemeGen Co. Ltd.
  • 31.7. Aurinia Pharmaceuticals Inc.
  • 31.8. Otsuka Pharmaceutical Co. Ltd.
  • 31.9. Equillium Inc.
  • 31.10. Anthera Pharmaceuticals Inc.
  • 31.11. Atara Biotherapeutics Inc.
  • 31.12. Artiva Biotherapeutics
  • 31.13. Caribou Biosciences
  • 31.14. Nkarta Inc.
  • 31.15. Adicet Bio Inc.

32. Global Lupus Nephritis Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Lupus Nephritis Market

34. Recent Developments In The Lupus Nephritis Market

35. Lupus Nephritis Market High Potential Countries, Segments and Strategies

  • 35.1 Lupus Nephritis Market In 2029 - Countries Offering Most New Opportunities
  • 35.2 Lupus Nephritis Market In 2029 - Segments Offering Most New Opportunities
  • 35.3 Lupus Nephritis Market In 2029 - Growth Strategies
    • 35.3.1 Market Trend Based Strategies
    • 35.3.2 Competitor Strategies

36. Appendix

  • 36.1. Abbreviations
  • 36.2. Currencies
  • 36.3. Historic And Forecast Inflation Rates
  • 36.4. Research Inquiries
  • 36.5. The Business Research Company
  • 36.6. Copyright And Disclaimer